Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized double-blind safety and efficacy trial.

Rigas, James R; Schuster, Michael W; Orlov, Sergey V; Milovanovic, Branislav M; Prabhash, Kumar; Smith, Jeffrey T

Rezultati

eNauka > Rezultati > Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized double-blind safety and efficacy trial.

Naziv:	Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized double-blind safety and efficacy trial.
Autori:	Rigas, James R; Schuster, Michael W; Orlov, Sergey V; Milovanovic, Branislav M; Prabhash, Kumar; Smith, Jeffrey T
Godina:	2010
Publikacija:	JOURNAL OF CLINICAL ONCOLOGY
ISSN:	0732-183X Journal of Clinical Oncology Pretraži identifikator
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 28 br. 15
WoS-ID:	000208852005002
URI:	https://enauka.gov.rs/handle/123456789/801173
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

Pronađi DOI

Pronalaženje DOI u servisu CrossRef-u na osnovu meta-podataka u zapisu. Prikazaće se DOI (i metapodaci) čiji se podaci najviše poklapaju. OPREZ - to ne mora biti ta publikacija.

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.